922 related articles for article (PubMed ID: 25555420)
21. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
23. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
[TBL] [Abstract][Full Text] [Related]
24. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
[TBL] [Abstract][Full Text] [Related]
25. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Shaw Y; Bilotti E; Zhou C; James DF; O'Brien S
Blood; 2015 Apr; 125(16):2497-506. PubMed ID: 25700432
[TBL] [Abstract][Full Text] [Related]
26. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
27. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Ahn IE; Underbayev C; Albitar A; Herman SE; Tian X; Maric I; Arthur DC; Wake L; Pittaluga S; Yuan CM; Stetler-Stevenson M; Soto S; Valdez J; Nierman P; Lotter J; Xi L; Raffeld M; Farooqui M; Albitar M; Wiestner A
Blood; 2017 Mar; 129(11):1469-1479. PubMed ID: 28049639
[TBL] [Abstract][Full Text] [Related]
28. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
30. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
35. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Brown JR; Barrientos JC; Barr PM; Flinn IW; Burger JA; Tran A; Clow F; James DF; Graef T; Friedberg JW; Rai K; O'Brien S
Blood; 2015 May; 125(19):2915-22. PubMed ID: 25755291
[TBL] [Abstract][Full Text] [Related]
36. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
37. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Sukbuntherng J; Chang BY; Clow F; Hedrick E; Buggy JJ; James DF; O'Brien S
N Engl J Med; 2013 Jul; 369(1):32-42. PubMed ID: 23782158
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
39. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Sharman JP; Farber CM; Mahadevan D; Schreeder MT; Brooks HD; Kolibaba KS; Fanning S; Klein L; Greenwald DR; Sportelli P; Miskin HP; Weiss MS; Burke JM
Br J Haematol; 2017 Feb; 176(3):412-420. PubMed ID: 27982425
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
